RxDoctor Payments Data

Michael Obiefune, MD

Family Medicine · Baltimore, MDNPI 1073552881

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $237,740 of the $291,118 with a category attached, or 81.7%. Viiv Healthcare Company accounts for 84.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $83,422 and has fallen 74.4% since, to $21,329 in 2025. Among family medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$291,118in general payments, 2019–2025

Across 513 payments — averaging $567.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$246K
  • Gilead$37K
  • Janssen Products, LP$6K
  • Johnson & Johnson$1K
  • Dynavax Technologies Corporation$342
  • Boehringer Ingelheim$331
  • plus $755 from 6 others

What the payments were for

  • Consulting fees$21,9008%
  • Speaking & faculty fees$237,74082%
  • Travel & lodging$15,6285%
  • Food & beverage$15,5635%
  • Education$2870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$291,118 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$46,374
Medicare patients
330
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine16$50,921
SuboxoneBuprenorphine Hcl/Naloxone Hcl23$8,273
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$4,497
Albuterol Sulfate HfaAlbuterol Sulfate31$1,114
Atorvastatin Calcium32$245
Amlodipine Besylate41$188
Fluticasone Propionate16$166
Losartan Potassium22$155
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$149
Doxycycline Hyclate16$142
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$110
Metformin Hcl20$79
Trazodone Hcl11$60
Lisinopril14$44
Prednisone29$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato$246,029$50,92116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →